RheumaGen, Inc. — Form D
RheumaGen, Inc. of DENVER, CO, a company, filed a Form D exempt-offering notice with the SEC on 2024-04-17. The offering totals $15.0M, of which $4.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-04-17
- Form: D
- Accession: 0001942974-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $15.0M
- Amount sold: $4.9M
- Remaining: $10.1M
- Investors: 3
- Date of first sale: 2024-04-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-510836
Issuer
- Name: RheumaGen, Inc.
- CIK: 0001942974
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 200 QUEBEC ST., DENVER, CO, 80230
- Phone: (720) 569-0180
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Bruce Michael Goodwin | Director | Denver, CO |
| James Brian Hart, Jr. | Executive Officer | Denver, CO |
| Bobak Robert Mozayeni | Executive Officer | Denver, CO |
| Ryan Kane Hart | Executive Officer | Denver, CO |
| Thomas Matthew Fratacci | Director | Denver, CO |
| Brian Matthew Freed | Executive Officer | Denver, CO |
| Richard Anthony Freed, III | Director | Denver, CO |
| Richard Anthony Freed, III | Executive Officer | Denver, CO |
| Brian M Freed | Director | Denver, CO |
| Brian M Freed | Executive Officer | Denver, CO |
| Gregory L Andrews | Director | Denver, CO |
Other filings by this issuer (3)
More